Phase 2 trial demonstrates 25% objective response rate and 90% disease control rate in patients with microsatellite stable colorectal cancer treated with envafolimab-suvemcitug-FOLFIRI combination.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.